Researchers from Tokyo Medical University presented data from a study that assessed microRNA (miRNA) profiles in extracellular vesicles (EVs) isolated from vitreous humor and serum of patients with ocular sarcoidosis and vitreoretinal lymphoma (VRL).
Over the past decade there has been much research into the use of induced pluripotent stem cells (iPSCs) as a cell therapy to regenerate tissue and treat heart disease. Now, one researcher has narrowed the focus down to treating heart disease not with whole cells, but with mitochondria derived from iPSCs. Gentaro Ikeda, a researcher at the Department of Medicine at Stanford University, has worked on generating extracellular vesicles (EVs) containing mitochondria from pluripotent stem cell-derived cardiomyocytes and administering these to restore the functionality of the myocardium in a porcine model of an infarct.
Mercy Bioanalytics Inc. stepped into the increasingly competitive early cancer detection field with a $41 million series A financing round to support its Halo liquid biopsy platform. Novalis Lifesciences led the oversubscribed round with participation from Sozo Ventures, Hatteras Venture Partners, Iselect Fund, American Cancer Society BrightEdge and Broadway Angels, an all-women venture capital group. Laboratory Corp. of America Holdings, Bruker Corp. and existing investors also contributed to the round.
While immune checkpoint inhibitors have revolutionized oncology, still only 20-30% of patients respond to PD-1/PD-L1 antibody monotherapy. This can be due to a failure of T cells to recognize “cold” tumors (low T-cell infiltrates).
Extracellular vesicles (EVs) are nanosized membrane vesicles released from a variety of cells that play important roles in cell-cell communication and which circulate in almost every body fluid, including blood, urine and cerebrospinal fluid (CSF).
The design of genetically modified exosomes that combine multiple targets killed cancer cells and conferred immunity against them. Scientists at the University of Southern California (USC) applied bioengineering techniques to introduce up to four antitumor functions in the same type of extracellular vesicles and destroy EGFR-positive triple-negative breast cancer (TNBC) tumor cells.
Tears shed today by patients frustrated by an inability to obtain a diagnosis could speed diagnoses for others in the future. Researchers at Wenzhou Medical University, China, have developed a new nano membrane system, dubbed I-Tears, that harvests and purifies tiny droplets called exosomes from tears, allowing rapid analysis for disease biomarkers.
Korean researchers at Sungkyunkwan University in Seoul have demonstrated that regenerative medicine using multipotent mesenchymal stem cell-derived extracellular vesicles could mitigate intraventricular hemorrhage-induced brain damage in newborn rats.
PERTH, Australia – Stem cell therapy has failed to deliver on its promises, according to Exopharm Ltd. founder and CEO Ian Dixon, who said he believes that exosomes, or the extracellular vesicles released by stem cells, could be a disrupter in the regenerative medicine space.
